Related Experiment Video
Updated: May 23, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
New drug targets in atopic dermatitis
Chemical Immunology and Allergy
|March 22, 2012
Summary
B cell depletion and T cell reduction therapies significantly improved moderate-to-severe atopic dermatitis (AD) symptoms and skin histology. These treatments reduced key inflammatory markers, suggesting potential therapeutic avenues for AD.
Area of Science:
- Immunology
- Dermatology
- Inflammation
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- T cells are implicated in AD pathogenesis, with potential B cell involvement.
- Existing treatments for moderate-to-severe AD have limitations.
Purpose of the Study:
- To investigate the efficacy of B cell depletion (anti-CD20 therapy) and T cell reduction (LFA3-IgG fusion protein) in patients with moderate-to-severe AD.
- To evaluate the impact of these therapies on clinical symptoms and histopathological features of AD.
Main Methods:
- Two pilot studies were conducted using monoclonal anti-CD20 antibody (rituximab) for B cell depletion.
- Alefacept (LFA3-IgG fusion protein) was used to reduce activated T cells.
- Clinical improvement, histological alterations, and inflammatory marker expression were assessed.
Main Results:
- Both rituximab and alefacept treatments led to significant improvement in skin symptoms and sustained effects.
- Histological features of AD, including spongiosis, acanthosis, and dermal infiltrates, showed dramatic improvement.
- Reduced expression of IL-5 and IL-13 was observed post-therapy.
- Allergen-specific IgE levels remained unchanged; total IgE levels decreased slightly with rituximab.
Conclusions:
- B cell depletion and T cell reduction therapies demonstrate efficacy in treating moderate-to-severe atopic dermatitis.
- These immunomodulatory approaches offer potential therapeutic strategies for AD by targeting key cellular players.
- Further research into neutralizing specific B and T cell products may benefit distinct patient subgroups.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...